TY - JOUR
T1 - Release abilities of adenosine diphosphate from phospholipid vesicles with different membrane properties and their hemostatic effects as a platelet substitute
AU - Okamura, Yosuke
AU - Katsuno, Shunsuke
AU - Suzuki, Hidenori
AU - Maruyama, Hitomi
AU - Handa, Makoto
AU - Ikeda, Yasuo
AU - Takeoka, Shinji
N1 - Funding Information:
The authors wish to thank Drs. N. Watanabe, K. Yokoyama and M. Murata at Keio University for the valuable discussion. This work was supported in part by Health and Labor Sciences Research Grants (Research on Pharmaceutical and Medical Safety, H.S., M.H., Y.I. and S.T.), Ministry of Health, Labor and Welfare , Japan. Y.O. was the recipient of a Research Fellowships from the Japan Health Sciences Foundation .
Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2010/12/20
Y1 - 2010/12/20
N2 - We have constructed phospholipid vesicles with hemostatic activity as a platelet substitute. The vesicles were conjugated with a dodecapeptide (HHLGGAKQAGDV, H12), which is a fibrinogen γ-chain carboxy-terminal sequence (γ400-411). We have recently exploited these vesicles as a potential drug delivery system by encapsulation of adenosine 5'-diphosphate (ADP) (H12-(ADP)-vesicles). Here we explore the relationship between the ADP release from H12-(ADP)-vesicles with different membrane properties and their hemostatic effects. In total, we prepared five kinds of H12-(ADP)-vesicles with different lamellarities and membrane flexibilities. By radioisotope-labeling, we directly show that H12-(ADP)-vesicles were capable of augmenting platelet aggregation by releasing ADP in an aggregation-dependent manner. The amount of ADP released from the vesicles was dependent on their membrane properties. Specifically, the amount of ADP released increased with decreasing lamellarity and tended to increase with increasing membrane flexibility. Our in vivo results clearly demonstrated that H12-(ADP)-vesicles with the ability to release ADP exert considerable hemostatic action in terms of correcting prolonged bleeding time in a busulphan-induced thrombocytopenic rat model. We propose a recipe to control the hemostatic abilities of H12-(ADP)-vesicles by modulating ADP release based on membrane properties. We believe that this concept will be invaluable to the development of platelet substitutes and other drug carriers.
AB - We have constructed phospholipid vesicles with hemostatic activity as a platelet substitute. The vesicles were conjugated with a dodecapeptide (HHLGGAKQAGDV, H12), which is a fibrinogen γ-chain carboxy-terminal sequence (γ400-411). We have recently exploited these vesicles as a potential drug delivery system by encapsulation of adenosine 5'-diphosphate (ADP) (H12-(ADP)-vesicles). Here we explore the relationship between the ADP release from H12-(ADP)-vesicles with different membrane properties and their hemostatic effects. In total, we prepared five kinds of H12-(ADP)-vesicles with different lamellarities and membrane flexibilities. By radioisotope-labeling, we directly show that H12-(ADP)-vesicles were capable of augmenting platelet aggregation by releasing ADP in an aggregation-dependent manner. The amount of ADP released from the vesicles was dependent on their membrane properties. Specifically, the amount of ADP released increased with decreasing lamellarity and tended to increase with increasing membrane flexibility. Our in vivo results clearly demonstrated that H12-(ADP)-vesicles with the ability to release ADP exert considerable hemostatic action in terms of correcting prolonged bleeding time in a busulphan-induced thrombocytopenic rat model. We propose a recipe to control the hemostatic abilities of H12-(ADP)-vesicles by modulating ADP release based on membrane properties. We believe that this concept will be invaluable to the development of platelet substitutes and other drug carriers.
KW - Adenosine 5'-diphosphate (ADP)
KW - Controlled release
KW - Lamellarity
KW - Membrane flexibility
KW - Phospholipid vesicles
KW - Platelet substitute
UR - http://www.scopus.com/inward/record.url?scp=78649776659&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649776659&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2010.09.013
DO - 10.1016/j.jconrel.2010.09.013
M3 - Article
C2 - 20875473
AN - SCOPUS:78649776659
SN - 0168-3659
VL - 148
SP - 373
EP - 379
JO - Journal of Controlled Release
JF - Journal of Controlled Release
IS - 3
ER -